Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.

RGLS

Regulus Therapeutics (RGLS)

Regulus Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:RGLS
DateHeureSourceTitreSymboleSociété
26/11/202414h00PR Newswire (US)Regulus Therapeutics Announces Participation at Upcoming Healthcare Investment ConferencesNASDAQ:RGLSRegulus Therapeutics Inc
08/11/202420h17Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:RGLSRegulus Therapeutics Inc
07/11/202422h26Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:RGLSRegulus Therapeutics Inc
07/11/202422h16Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RGLSRegulus Therapeutics Inc
07/11/202422h05PR Newswire (US)Regulus Therapeutics Reports Third Quarter 2024 Financial Results and Recent UpdatesNASDAQ:RGLSRegulus Therapeutics Inc
08/10/202414h00PR Newswire (US)Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)NASDAQ:RGLSRegulus Therapeutics Inc
28/08/202414h00PR Newswire (US)Regulus Therapeutics Announces Participation at Two Healthcare Investment ConferencesNASDAQ:RGLSRegulus Therapeutics Inc
08/08/202422h05PR Newswire (US)Regulus Therapeutics Reports Second Quarter 2024 Financial Results and Recent UpdatesNASDAQ:RGLSRegulus Therapeutics Inc
06/08/202414h00PR Newswire (US)Regulus Therapeutics to Present at the Canaccord Genuity 44th Annual Growth ConferenceNASDAQ:RGLSRegulus Therapeutics Inc
29/07/202422h18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RGLSRegulus Therapeutics Inc
24/06/202416h00AllPennyStocks.comThis Biotech Wasted No Time Stealing The Premarket ShowNASDAQ:RGLSRegulus Therapeutics Inc
24/06/202413h00PR Newswire (US)Regulus Therapeutics Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)NASDAQ:RGLSRegulus Therapeutics Inc
04/06/202414h00PR Newswire (US)Regulus Therapeutics Announces Expected Addition to the Russell 3000® and Russell 2000® IndexesNASDAQ:RGLSRegulus Therapeutics Inc
20/05/202422h11Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:RGLSRegulus Therapeutics Inc
16/05/202414h00PR Newswire (US)Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical OfficerNASDAQ:RGLSRegulus Therapeutics Inc
09/05/202422h54Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:RGLSRegulus Therapeutics Inc
09/05/202422h05PR Newswire (US)Regulus Therapeutics Reports First Quarter 2024 Financial Results and Recent UpdatesNASDAQ:RGLSRegulus Therapeutics Inc
06/05/202414h00PR Newswire (US)Regulus Therapeutics Advances to Cohort 4 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)NASDAQ:RGLSRegulus Therapeutics Inc
30/04/202414h00PR Newswire (US)Regulus Therapeutics to Participate in the Canaccord Genuity Genetic Medicine for Generalists Webcast SeriesNASDAQ:RGLSRegulus Therapeutics Inc
21/03/202421h05PR Newswire (US)Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent UpdatesNASDAQ:RGLSRegulus Therapeutics Inc
12/03/202411h32PR Newswire (US)Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of EquityNASDAQ:RGLSRegulus Therapeutics Inc
12/03/202411h30PR Newswire (US)Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)NASDAQ:RGLSRegulus Therapeutics Inc
10/01/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:RGLSRegulus Therapeutics Inc
02/01/202422h05PR Newswire (US)Regulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)NASDAQ:RGLSRegulus Therapeutics Inc
27/12/202322h16Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:RGLSRegulus Therapeutics Inc
22/11/202314h00PR Newswire (US)Regulus Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx ConferenceNASDAQ:RGLSRegulus Therapeutics Inc
09/11/202322h05PR Newswire (US)Regulus Therapeutics Reports Third Quarter 2023 Financial Results and Recent UpdatesNASDAQ:RGLSRegulus Therapeutics Inc
02/11/202313h00PR Newswire (US)Regulus Therapeutics Announces First Patient Dosed in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)NASDAQ:RGLSRegulus Therapeutics Inc
19/10/202314h00PR Newswire (US)Regulus Therapeutics Advances to Cohort 3 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)NASDAQ:RGLSRegulus Therapeutics Inc
20/09/202313h00PR Newswire (US)Regulus Therapeutics Announces Positive Topline Data from the First Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)NASDAQ:RGLSRegulus Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:RGLS

Dernières Valeurs Consultées